Effects of two pediatric vaccines on autoimmune diabetes in NOD female mice

Toxicology Letters

Volumn 146, Issue 1, 2003, Pages 93-100

  Ravel, Guillaume ^a,b   Christ, Marielle ^a   Liberge, Pierre ^a   Burnett, Roger ^a   Descotes, Jacques ^b  

^a MDS Pharma Services   (France)

^b EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Autoimmunity; Diabetes; Immunotoxicity; NOD mice; Vaccine

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE; DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; INACTIVATED VACCINE; INFANRIX POLIO ENF; INFANRIX POLIO HIB NOUR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GLUCOSE BLOOD LEVEL; IMMUNOSTIMULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; STATISTICAL ANALYSIS; VACCINATION;

HAEMOPHILUS;

EID: 0242654096     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2003.09.005     Document Type: Article

References (41)

1. Ada G. Vaccines and vaccination. New Engl. J. Med. 345:2001;1042-1453.
2. Adorini L., Gregori S., Harrison L.C. Understanding autoimmune diabetes: insights from mouse models. Trends Mol. Med. 8:2002;31-38.
3. Albert L.J., Inman R.D. Molecular mimicry and autoimmunity. New Engl. J. Med. 341:1999;2068-2074.
4. Aron-Maor A., Shoenfeld Y. Vaccination and systemic lupus erythematosus: the bidirectional dilemmas. Lupus. 10:2001;237-240.
5. Atkinson M.A., Leiter E.H. The NOD mouse model of type 1 diabetes: as good as it gets? Nat. Med. 5:1999;601-604.
6. Benjamin C., Chew G.C., Silman A.J. Joint and limb symptoms in children after immunisation with measles, mumps, and rubella vaccine. Br. Med. J. 304:1992;1075-1078.
7. Chen R.T., Pless R., Destefano F. Epidemiology of autoimmune reactions induced by vaccination. J. Autoimmun. 16:2001;309-318.
8. Classen J.B. The timing of immunization affects the development of diabetes in rodents. Autoimmunity. 24:1996;137-144.
9. Classen J.B., Classen D.C. Hemophilus vaccine associated with increased risk of diabetes: causality likely. Diabetes Care. 23:2000;872-873.
10. Classen J.B., Classen D.C. Vaccines and the risk of insulin-dependent diabetes (IDDM): potential mechanism of action. Med. Hypotheses. 57:2001;532-538.
11. Confavreux C., Suissa S., Saddier P., Bourdes V., Vukusic S. Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group. New Engl. J. Med. 344:2001;319-326.
12. Davidson A., Diamond B. Advances in immunology: autoimmune diseases. New Engl. J. Med. 345:2001;340-350.
13. Del Giudice G., Podda A., Rappuoli R. What are the limits of adjuvanticity? Vaccine. 20:2001;38-41.
14. Descotes J., Ravel G., Ruat C. Vaccines: predicting the risk of allergy and autoimmunity. Toxicology. 174:2002;45-51.
15. DeStefano, F., Mullooly, J.P., Okoro, C.A., Chen, R.T., Marcy, S.M., Ward, J.I., Vadheim, C.M., Black, S.B., Shinefield, H.R., Davis, R.L., Bohlke, K., Vaccine Safety Datalink Team, 2001. Childhood vaccinations, vaccination timing, and risk of type 1 diabetes mellitus. Pediatrics 108, E112.
16. Diamantstein T. Stimulation of humoral immune response by tilorone hydrochloride. Immunology. 24:1973;771-775.
17. Elliman D. Vaccination and type 1 diabetes mellitus. Br. Med. J. 318:1999;1159-1160.
18. Fournie G.J., Mas M., Cautain B., Savignac M., Subra J.F., Pelletier L., Saoudi A., Lagrange D., Calise M., Druet P. Induction of autoimmunity through bystander effects. Lessons from immunological disorders induced by heavy metals. J. Autoimmun. 16:2001;319-326.
19. Gellin B.G., Schaffner W. The risk of vaccination - the importance of "negative" studies. New Engl. J. Med. 344:2001;372-373.
20. Graves P.M., Barriga K.J., Norris J.M., Hoffman M.R., Yu L., Eisenbarth G.S., Rewers M. Lack of association between early childhood immunizations and beta-cell autoimmunity. Diabetes Care. 22:1999;1694-1697.
21. Heijbel H., Chen R.T., Dahlquist G. Cumulative incidence of childhood-onset IDDM is unaffected by pertussis immunization. Diabetes Care. 20:1997;173-175.
22. Im S.H., Barchan D., Feferman T., Raveh L., Souroujon M.C., Fuchs S. Protective molecular mimicry in experimental myasthenia gravis. J. Neuroimmunol. 126:2002;99-106.
23. Jefferson T., Heijbel H. Demyelinating disease and hepatitis B vaccination: is there a link? Drug Safety. 24:2001;249-254.
24. Kaibara N., Takagishi K., Hotokebuchi T., Morinaga M., Arita C., Arai K. Enhancing effects of tilorone on collagen arthritis and humoral immune response to type II collagen. Clin. Immunol. Immunopathol. 42:1987;311-318.
25. Karvonen M., Cepaitis Z., Tuomilehto J. Association between type 1 diabetes and Haemophilus influenzae type b vaccination: birth cohort study. Br. Med. J. 318:1999;1169-1172.
26. Levine S., Sowinski R., Abreu S.L. Suppression of experimental allergic encephalomyelitis by tilorone: cell transfer and interferon studies. Immunopharmacology. 6:1983;23-30.
27. Levine S., Sowinski R., Albrecht W.L. T-lymphocyte depletion induced in rats by analogs of tilorone hydrochloride. Toxicol. Appl. Pharmacol. 40:1997;137-145.
28. Makino S., Kunimoto K., Muraoka Y., Katagiri K. Effect of castration on the appearance of diabetes in NOD mouse. Jikken Dobutsu. 30:1981;137-140.
29. McDevitt H. Closing in on type 1 diabetes. New Engl. J. Med. 345:2001;1060-1061.
30. Megel H., Raychaudhuri A., Goldstein S., Kinsolving C.R., Shemano I., Michael J.G. Tilorone: its selective effects on humoral and cell-mediated immunity. Proc. Soc. Exp. Biol. Med. 145:1974;513-518.
31. Okanoue T., Sakamoto S., Itoh Y., Minami M., Yasui K., Sakamoto M., Nishioji K., Katagishi T., Nakagawa Y., Tada H., Sawa Y., Mizuno M., Kagawa K., Kashima K. Side effects of high-dose interferon therapy for chronic hepatitis C. J. Hepatol. 25:1996;283-291.
32. Older S.A., Battafarano D.F., Enzenauer R.J., Krieg A.M. Can immunization precipitate connective tissue disease? Report of five cases of systemic lupus erythematosus and review of the literature. Semin. Arthritis Rheum. 29:1999;131-139.
33. Olson J.K., Croxford J.L., Calenoff M.A., Dal Canto M.C., Miller S.D. A virus-induced molecular mimicry model of multiple sclerosis. J. Clin. Invest. 108:2001;311-318.
34. Robles D.T., Eisenbarth G.S. Type 1A diabetes induced by infection and immunization. J. Autoimmun. 16:2001;355-362.
35. Ropper A.H., Victor M. Influenza vaccination and the Guillain-Barre syndrome. New Engl. J. Med. 339:1998;1845-1846.
36. Sasmaz R., Altinyazar H.C., Tatlican S., Eskioglu F., Yurtsever P. Recurrent lupus vulgaris following repeated BCG (Bacillus Calmette Guerin) vaccination. J. Dermatol. 28:2001;762-764.
37. Shoenfeld Y., Aron-Maor A. Vaccination and autoimmunity - 'vaccinosis': a dangerous liaison? J. Autoimmun. 14:2000;1-10.
38. Silveira P.A., Baxter A.G. The NOD mouse as a model of SLE. Autoimmunity. 34:2001;53-64.
39. Vial T., Choquet-Kastylevsky G., Descotes J. Adverse effects of immunotherapeutics involving the immune system. Toxicology. 174:2002;3-11.
40. Walker S.E. Accelerated mortality in young NZB/NZW mice treated with the interferon inducer tilorone hydrochloride. Clin. Immunol. Immunopathol. 8:1977;204-212.
41. Wucherpfennig K.W. Mechanisms for the induction of autoimmunity by infectious agents. J. Clin. Invest. 108:2001;1097-1104.